Table 2.
Distribution of clinical and prognostic features according to F3T3 status
| FGFR3-TACC3+ | FGFR3-TACC3- | P value | |
|---|---|---|---|
| Clinical features of the IDH wildtype glioma cohort (grades II‒IV), n = 969 | |||
| Sex ratio (M/F) | 1.19 | 1.51 | 0.33 |
| Median age at diagnosis, y (range) | 57 (25–87) | 61 (15–90) | 0.20 |
| Median KPS score (range) | 80 (40–100) | 80 (40–100) | 0.68 |
| Surgery at diagnosis (available records), n (%) | |||
| • Surgery | 54 (72) | 411 (79) | 0.20 |
| • Biopsy | 21 (28) | 112 (21) | |
| MGMT promoter methylation/tested | 15/47 (32) | 129/268 (48) | 0.04 |
| Clinical features of the IDH wildtype and IDH NOS GBM subgroup, n = 784 | |||
| Sex ratio (M/F) | 1.20 | 1.56 | 0.31 |
| Median age at diagnosis, y (range) | 58 (35–87) | 63 (21–90) | 0.05 |
| Median KPS score, range | 80 (40–100) | 80 (40–100) | 0.55 |
| Surgery at diagnosis (available records), n (%) | |||
| • Surgery | 47 (76) | 359 (80) | 0.42 |
| • Biopsy | 15 (24) | 89 (20) | |
| First line treatment after surgery, n (%) | 0.20 | ||
| • RT plus concomitant and adjuvant TMZ | 51 (84) | 333 (76) | |
| • Other treatments | 10 (16) | 103 (24) | |
| MGMT promoter methylation/tested (%) | 13/40 (33) | 112/239 (47) | 0.09 |
Note. In the whole cohort of 969 IDH wildtype diffuse gliomas (upper part) and in the subgroup of 581 IDH wildtype/IDH NOS glioblastoma patients (lower part).